Aortic Aneurysm Market Regional Analysis:
North American Market Insights
The aortic aneurysm market in North America is forecasted to hold the largest revenue share of 40% by throughout the analyzed timeline. Significant driving factors in the region include the presence of top-notch healthcare infrastructure and concentrated focus on R&D units to procure new approaches of treating AA. For instance, in August 2023, the American Heart Association awarded USD 750,000.0 to accelerate the collaborative project of developing an early, minimally invasive treatment, named Clickable Extracellular Vesicles for Aneurysm Stabilization. It was led by a team of researchers from the University of Pittsburgh Swanson School of Engineering and Carnegie Mellon University Biomedical Engineering. Such advancements are further widening business opportunities in this landscape.
The mortality rate of AAA in the U.S. was calculated to be 15,000 per year in 2021 (ScienceDirect). Thus, healthcare professionals in this country are opting for advanced procedures, available in the market, to minimize patient impediment and reduce required time for operation. For instance, in March 2024, a well-known vascular surgeon from UC Davis Health earned FDA approval for using physician modified aortic endografts (PMEGs) to treat various complex aortic aneurysms. This was also a part of the clinical trial for full-scale commercialization of this device. Such regulatory support, coupled with the surging demand, is fostering a profitable atmosphere for the AA merchandise in this country.
APAC Market Insights
The Asia Pacific aortic aneurysm market is set to witness the highest growth through 2035. The strong emphasis of various key players on this region is propelling its pace of growth in this field. Additionally, they are investing heavily in developing innovative medical products to help professionals treat the growing susceptible population China, India, and Japan. Besides, regulatory bodies from these landscapes are also promoting the nationwide use of associated restoration devices. Furthermore, the enlarging volume of patients with cardiovascular disease (CVD) across the region is also a driving factor in this sector. For instance, in 2022, the prevalences of IHD in Central Asia and South Asia were 8,573.3 per 100,000 and 2,214.6 per 100,000.
India is emerging as a lucrative investment opportunity for global leaders in the market, attributable to its large patient pool and advancing healthcare industry. The initiatives from both public and private organization to prevent the widespread of related vascular diseases are fueling demand in this category. On this note, in September 2024, Fortis Escorts Heart Institute a dedicated facility to offer complete diagnosis and treatment for aortic diseases, Aorta Centre. This entity is fully equipped to avail all kinds of surgical, endovascular, and hybrid interventions, along with radiological diagnosis. These efforts are further attracting more companies to invest in this sector.
